1,25(OH)2D3 is the active metabolite of vitamin D3 and its action is mediated by an intracellular receptor (VDR) which binds to DNA (Mangelsdorf et al., 1984; Reichel et al., 1989) . The presence of the VDR in cells of the immunohaemopoetic system first indicated 1,25(OH)2D3 may have a role in regulating their activity. 1,25(OH)2D3 has been shown in vitro to have an antiproliferative effect and promote differentiation in monoblastic and promyelocytic cell lines, to inhibit differentiation in K562 leukaemia cells, to inhibit IL-1 production, to suppress CD4+T cell proliferation and IL2 production and inhibit immunoglobulin production by B cells (Jordan et al., 1990; Rebel et al., 1992; Tsoukas et al., 1989; Rigby et al., 1987; Moore et al., 1991; Iho et al., 1986; Tsoukas et al., 1984; Bhalla et al., 1989) . In a number of cell lines the degree of response to 1,25(OH)2D3 appears to be dependent on the level of ligand binding (Chen et al., 1986 ) however the precise relationship is unknown. Furthermore 1,25(OH)2D3 has been shown to modulate expression of its own receptor (Lee et al., 1989; Strom et al., 1989) . In actively proliferating lymphocytes VDR expression appears to be high and correlates with proliferative status except in B-cells in which expression is low (Kizaki et al., 1991 (Norman et al., 1990; Zhou et al., 1989; Binderup & Bramm, 1988; Colston et al., 1992 (Yunis et al., 1987; Weiss et al., 1987) .
The aim of this study was to investigate the antiproliferative effect and the induction of differentiation of vitamin D3 on t(14;18) lymphoma cell lines and relate this to expression of the VDR in lymphoma tumour biopsy material. 1,25(OH)2D3 and an analogue, MC903 (calcipotriol) which has equivalent VDR binding affinity but 100 fold less effect on Ca2+ metabolism were assayed.
Materials and methods

Cells
The cell lines studied for their response to 1,25(OH)2D3 and MC903 were as follows: SU-DHL4 and SU-DUL5 (both derived from high grade B cell lymphoms): each carries a t(14;18) with an associated rearrangement of the bc12 gene; in SU-DHL4 rearrangement through the major breakpoint region (Cleary et al., 1986a) and SU-DUL5 rearrangement through the minor cluster region (Cleary et al., 1986b) . U937 is a monoblastic cell line for which both 1,25(OH)2D3 and MC903 have been shown to inhibit proliferation and promote differentiation along the monocytic/macrophage pathway. SU-DHL4 cells were a gift from Dr A. Epstein (UCLA, Los Angeles, CA), SU-DUL5 cells were a gift from Dr M. Cleary (Stanford, CA) . Cells were cultured in medium supplemented with 10% foetal bovine serum in humidified atmosphere with 5% C02. a stock concentration of 10-3 M and stored at -20°C and protected from light. Dilutions of the stock solutions were made in ethanol and then medium. The maximum concentration of ethanol in culture (0.1%) did not influence cell growth.
Modulation of cell proliferation and analysis of differentiation Cells in log phase growth were seeded at 2 x I0O cell ml-' and either agent (or vehicle = control) were added at the required concentration. Cells were counted daily using a Coulter counter and assayed for viability with (Colston et al., 1980) . Cytosol protein concentration was determined by the method of Bradford (Bradford, 1976) . The experiment was performed in duplicate and repeated once.
Tumour samples and assay for VDR expression Tumour biopsy specimens were snap frozen and 5 ytm cryostat sections were mounted onto poly-l-lysine coated slides and fixed in 4% formaldehyde and methanol and washed in phosphate buffered saline. (Fixed sections were stored at -20°C in glycerol/sucrose storage medium before staining.) Sections were analysed for the presence of the VDR using a Vectastain ABC anti-rat alkaline phosphatase kit with the monoclonal antibody 9A7a (provided by Dr J. Wesley Pike). The alkaline phosphatase substrate contained a levamisole block. Sections were processed in duplicate. The MCF-7 cell line which has a high level of VDR expression served as the positive control.
Results
Effect of 1,25(OH)2D3 and MC903 on cell proliferation These agents inhibited the proliferation of SU-DHL4 and SU-DUL5 with no effect on cell viability (Figure 1 ) at 10-7 M. There was no effect on proliferation at lower concentrations. U937 was inhibited at lower concentrations of each as recorded elsewhere (Binderup & Bramm, 1988) . At 10-7 M there was an approximately 50% reduction of proliferation of SU-DHL4 and SU-DUL5 on day 4.
Effect of 1,25(OH)2D3 and MC903 on induction of differentation (Table I) SU-DHL4 acquired markers of mature B-cell differentiation (Bi, B4 and CD38) whilst SU-DUL5 lost a marker of immaturity (CD 14) There was no effect of either agent at lower concentrations (10-8 to 10-9M, data not shown). (Umetsu et al., 1990) indicating a possible role for CD4+T cells in promoting follicular NHL. 1,25(OH)2D3 inhibits CD4+T cell proliferation over a concentration range I0-'-10-1 M and this effect on CD4+T cells appears to be both direct and also indirect through suppression of ILl production by monocytes (Jordan et al., 1990; Tsoukas et al., 1989; Rigby, 1988; Binderup, 1992) . Therefore the antifollicular NHL effect of 1,25(OH)2D3 may be mediated (at least in part) by an inhibitory effect on CD4+T cells. The development of the bcl2 transgenic mouse (McDonnell et al., 1989 ) provides a novel model of follicular NHL and may enable an in vivo analysis of the interplay between B and T cells under the influence of 1,25(OH)2D3 and its analogues. Certainly the t(14;18) cell lines are limited as a model of follicular NHL since they are derived from high grade B cell lymphomas. Nevertheless, if the antiproliferative and differentiationpromoting effect produced by 1,25(OH)2D3 on the SU-DHL4 and SU-DUL5 cell lines extends to lymphoma of follicle centre cell type, then using 1,25(OH)2D3 analogues it may be possible to achieve serum levels that act directly on the centrocytes, in addition to the postulated indirect mechanism of T cell inhibition, without perturbing calcium metabolism.
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